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 The Indiana Clinical and Translational Science Institute (ICTSI) was designed with input from a wide variety of critical stakeholders across the entire state of Indiana to 
create a vibrant engine for “Translational Sciences” research 
and training. Th e Institute was established in 2008 with a CTSA 
grant from the National Institute of Health (NIH) awarded to the 
Indiana University (IU) School of Medicine and a consortium 
of three leading universities in the state that includes Indiana, 
Purdue and Notre Dame Universities. It brought together a wide 
array of the state’s government, hospital, industry, and foundation 
partners to engage all of the key stakeholders in health sciences 
research (see  Figure 1 ). Th us, ICTSI is in a unique position to 
infl uence biomedical education in the state of Indiana, investigate 
the majority of Indiana’s population health data through medical 
informatics capabilities, and exert statewide infl uence in both 
public and private health services through our partnerships. In 
short, the ICTSI was created to be  a true statewide laboratory to 
explore innovative methods aimed at transforming research in health 
economics, health care delivery, and health policy. Although the 
ICTSI is designed to meet all of the traditional goals of a CTSA 
award such as training and career development, providing research 
infrastructure to academic investigators including the Clinical 
Research Center (CRC), and community engagement programs, 
this report will specifi cally focus on some of the programs that 
illustrate our approach to developing successful public–private 
partnerships to advance translation research and training. 
 From the beginning, ICTSI was conceived as a partnership 
between academia and private stakeholders and many of our 
private partners were included in the earliest meetings as we 
were coalescing to write the grant. Th is early writing period 
spanned nearly a year of biweekly meetings where many of the 
representatives from our business and private partners were 
regular participants. Th ese intense interactions lead to some key 
insights about what it takes to build successful public private 
partnerships:
 1.   Listen and understand each others’ perspectives and priorities 
to create meaningful communications with potential 
partners. 
2.   Identify mutually benefi cial areas of collaboration all the 
while being sensitive to issues of ownership, confl icts of 
interest and intellectual property rights. 
3.   Develop clearly defi ned sets of goals, deliverables and metrics 
for the collaborative programs. 
4.   Engage the key personnel from all sides in leadership roles 
for the program. 
 
 Based on these principles, we have developed and are still 
developing a number of partnerships. We will describe examples 
of the major Academic-Private Collaborations of the Indiana 
CTSI in areas of building research infrastructures and training 
physician scientists. 
 Many of ICTSI’s public–private collaborations span the 
full range of T1 through T4 translation areas. Th e concept of 
Translational Sciences that is envisioned for the ICTSI supports 
the smooth fl ow of ideas and discoveries along a series of steps 
within a “Translational Cycle” (see  Figure 2 ). It starts with 
studies that take “bench” fi ndings to controlled clinical trials at 
the “bedside” (Translation level 1); then moves to studies that 
test results obtained in controlled discovery settings to larger 
patient populations (Translation level 2); which leads to studies of 
translation of such fi ndings of clinical eff ectiveness into practice 
across communities (Translation level 3); and fi nally bringing the 
knowledge gained from responses back to the “laboratory” for 
further study and refi nement (Translation level 4), thus creating 
the reiterative process of transformation. Th e following are a few 
examples of the partnerships across this translational cycle. 
 T1 Translation: developing a phase I unit with a commercial 
clinical research organization (CRO) 
 One of the obstacles for translating many discoveries from academic 
laboratories into eff ective therapies is the inability to access a fully 
good clinical practice (GCP) compliant, commercial grade unit 
by academic investigators to conduct phase I studies that satisfy 
FDA registration. Currently these studies have to be conducted in 
commercial units that are expensive, requiring signifi cant commercial 
fund raising that is beyond the scope of most academic researchers. 
Th is resource shortage is particularly acute in areas such as oncology 
where even early phase studies have to be conducted in patients with 
the relevant disease; even large established pharmaceutical companies 
are fi nding this to be a bottle neck for translation. Th us, there is great 
need for academic center based, commercial grade phase I units that 
enroll severely ill patients in phase I trials to discover new therapies 
rapidly. On the other side, from the CTSI perspective, while most 
CRCs run by CTSA institutions conduct clinical trials in patients, 
they do not typically have the fi nancial resources to maintain the 
infrastructure to conduct GCP compliant, FDA registration phase 
I studies. Many of the CRCs are struggling even to recoup minimal 
costs back from the standard clinical studies they are supporting. 
Th us, a mutually benefi cial approach may be to partner with a 
commercial CRO and large pharmaceutical companies to create a 
phase I unit at an academic medical center. 
 Th e ICTSI has been developing such a program to create a Phase 
I unit with an oncology focus at IU Hospital. We have partnered 
with a commercial CRO, Veeda Clinic Research/Veeda Oncology, 
which is a full service global CRO specializing in the early clinical 
development of drugs. Veeda has state-of-the-art facilities in the 
United Kingdom, India and Malaysia. Veeda provides a full range 
of services in phase I and IIa clinical research, has won Frost and 
Sullivan’s “Partner of Choice” for phase I studies in 2007 and is a 
current contract vendor to Eli Lilly globally. Veeda brings CRO 
management expertise and an established global brand with a 
business development infrastructure that can be used to support 
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the new clinic’s operations. Th is would be their fi rst US-based 
unit and their fi rst academic partnership in the United States. We 
then specifi cally engaged the IU Simon Cancer Center researchers 
and physicians who wish to test novel therapies they would like 
to make available to their patients. Th ese physicians have access 
to patients with cancer, an important and unique “asset” for early 
phase clinical studies, particularly in oncology. Th irdly, we brought 
in the hospital management to work out the space and service lease 
agreements. Fourth component of this was to engage a sponsor 
who could begin placing studies in such a unit. Here, we have 
been supported strongly by the Lilly oncology discovery group 
who see the benefi ts of creating an accessible, high quality unit 
like this near their headquarters in Indianapolis. 
 Finally, BioCrossroads, Indiana’s initiative to help grow Indiana’s 
life sciences economy, which provides commercial investment and 
grant funding to emerging life science opportunities, launches new 
life sciences businesses, and forms and expands collaborations 
and partnerships among Indiana’s life science institutions, played 
critical facilitator role in developing this program. For example, 
BioCrossroads provided a full time project manager to develop 
the phase I unit related business venture with ICTSI. Th us, by 
connecting a variety of key constituents with mutually benefi cial 
goals, we are creating a unique model of a CRC. Th e primary focus 
will be to conduct trials of novel therapies. However, we have also 
designed the unit to have excess capacity so that many of the NIH 
clinical studies at IU School of Medicine can be conducted for 
minimal costs, providing signifi cant relief to the traditional CRC, 
which is always resource constrained. 
 T2 Translation: creating clinical 
research infrastructure with 
Indiana University Health, the 
state’s largest hospital system 
 Since early 2010, Clarian Health 
Partners, the state’s largest and 
one of the nation’s largest hospital 
systems has been working with 
the IU School of Medicine to form 
what is now called IU Health. IU 
Health includes IU Hospital, 
Methodist Hospital, Riley Hospital 
for Children, Clarian West and 
North Hospitals, and 20 other 
hospitals statewide. Th is network 
has provided an exceptional 
opportunity for ICTSI to partner 
with IU Health and facilitate 
clinical research across Indiana. 
Th e leadership of IU Health has 
made research and education two 
of the key metrics of success for 
the entire health system. Th rough 
joint strategic planning with IU 
School of Medicine, IU Health will 
invest signifi cant resources to help 
recruit patients into clinical trials, 
assist with biological specimen 
collection and create a single IRB 
infrastructure that will eventually 
cover all hospitals statewide. Th e 
CEO of IU health, Dan Evans has 
laid out a policy where predefi ned 
milestones for each hospital facility demonstrating research 
support such as the number of patients enrolling in clinical trials 
and donating biological specimens for research would in part 
determine the fi nancial compensation of the hospital CEO and 
senior administrators. 
 T3 Translation: creating patient-centered research capabilities 
with Regenstrief Institute and Indiana Health Information 
Exchange (IHIE) 
 The ICTSI, in collaboration with Regenstrief Institute, a 
private nonprofi t organization that has been a national leader 
in medical informatics, has established the Central Indiana 
Innovation Network (CI-Net) to provide researchers access to 
the Indiana CTSI’s integrated informatics network of networks 
found throughout the state of Indiana. Th e central goal of 
CI-Net is to enhance subject recruitment from participating 
practices into a wide variety of studies by importing registration 
and contact data and upcoming appointments from registration 
and scheduling systems. Patients eligible for study recruitment 
are approached by research assistants who are anchored within 
and affi  liated with each practice. Th is approach works extremely 
well for large practices with large numbers of patients; two-
thirds of study participants have been minorities. However, 
Indiana has thousands of smaller practices whose physicians 
are oft en interested in having their patients participate in the 
latest clinical research involving innovative interventions. Yet, 
it is not feasible to have a research assistant at each of these 
smaller practices. 
 Figure 1.  His schematic diagram illustrating some of the Public–Private partnerships of the Indiana CTSI. Regenstrief Institute—a 
nonprofi t organization and nationally recognized medical informatics research; Indiana University Health—Indiana’s larget and 
the one of the nation’s largets hospital systems; Eli Lilly—large pharama based in Indianapolis; Lilly Endowment—one of the 
nation’s largest philanthropic organizations; BioCrossroads—Indiana’s economic development initiative; Richard M. Fairbanks 
Foundation—an Indianapolis based philanthropic organization; Veeda Clinical Research—a global CRO; WellPoint—the nation’s 
larget health insurer; IHIE—Indiana Health Information Exchange; Docs4Docs—a coomercial messaging system delivering test 
results to physician offi ces across Indiana; Cook Group—one of the nation’s largest device companies. 
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 To communicate with both small and large practices, 
Regenstrief Institute has developed a clinical messaging system 
called the DOCS4DOCS ® (D4D) Service. Th is system, run by the 
not for profi t business entity called Indiana Health Information 
Exchange (IHIE) in conjunction with Regenstrief Institute, delivers 
laboratory and other clinical results from the participating data 
sources (e.g., a hospital’s laboratory) to the intended responsible 
provider. Results can also be transmitted via Health Level Seven 
(HL7) directly to a practice’s electronic medical record or via 
fax. Th e D4D Service delivers electronic copies of discharge 
summaries, operative notes, EKGs, and radiology reports from 
over 35 hospitals in Indiana, and more are being added. Over 36 
million messages have been delivered to nearly 19,000 physicians 
throughout Indiana. 
 Th e D4D System provides Regenstrief/IHIE with a direct 
connection to the physician’s practice. It is also a channel that 
can be used to provide other services. For example, Regenstrief 
Institute is currently developing the capability to annotate a 
laboratory report with patient-specifi c reminders or comments 
about a new research result that may apply. Regenstrief Institute 
delivers adaptive turnaround documents to physicians that allow 
these physicians to provide feedback, complete forms within D4D, 
and deliver completed and verifi ed forms to applications that can 
then extract data. Additionally, discussions with public health 
offi  cials are underway to explore 
how the D4D Service could be 
used for public health alerts. Th e 
capability for a notifi cation to all 
practices is currently built into 
the system and is used to make 
various announcements and 
deliver information to practices. 
D4D has a 24/7 Helpdesk to 
support the needs of practices. 
We are now expanding CI-Nets 
reach to the 19,000 physicians in 
smaller practices; we posit this 
will greatly increase the yield of 
subject recruitment for clinical 
research in real world settings. 
We will develop an informatics-
based solution to enable access to 
engage the practices in D4D. Th is 
connectivity with a large number 
of physicians’ offi  ces also creates 
an ideal platform for conducting 
“real life” comparative eff ectiveness 
research of many standard 
treatment protocols. By connecting 
all of the practices in IU Health to 
clinical trials and naturalistic health 
outcome studies, this program also 
provides a natural link to T2 and 
T3 research activities across our 
statewide health care system. 
 T4 Translation: training program 
in disease and quantitative 
modeling with Eli Lilly 
 We partnered with Eli Lilly to 
create a unique career development 
program for young faculty titled “Disease and Therapeutic 
Response Modeling Program.” Th e training curriculum was 
designed to generate quantitative models of disease and drug eff ect 
that can be used to catalyze the movement of new diagnostics and 
therapies along the translational continuum. Th is was organized 
as a career development academic program designed to train K 
scholars in the use of quantitative modeling tools to improve the 
eff ectiveness of translational medicine. Specifi cally, we expect 
that the models of disease, disease-progression, and therapeutic 
eff ect generated by the faculty and fellows trained in this program 
will provide a unique body of data. Th ese would include data that 
can be refi ned and improved over time to aid in the translation 
of multiple potentially valuable biomarkers of therapeutic eff ect 
into the clinic and to improve the rate of translation of targeted 
therapeutic agents. 
 Th e program involved identifying three major areas of mutually 
benefi cial goals: increase both partners capability of disease state 
modeling by training individuals in specifi c competencies; develop 
major disease-state and disease-progression models; and make 
these models publicly available throughout the CTSI network. 
Th is would be a major benefi t to the pharmaceutical industry in 
general, and was an attractive win-win scenario for Eli Lilly and 
ICTSI. Th is new program was designed to bring the science of 
quantitative modeling to our eff orts to translate new tests and 
 Figure 2.  The schematic diagram represents the concept of the translational circle beginning from the bench, progressing 
through to the bedside, then community and eventually coming back as new knowledge for further research.  Also shown are 
the four exemplary public–private partnerships of the Indiana CTSI at each of these steps. 
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therapies from the laboratory into the clinic and to the community. 
Its ultimate purpose is to catalyze eff ective translational medicine 
through the rigorous application of quantitative models at each 
stage of the translational process within the ICTSI. Implicit within 
this eff ort was the drive toward more personalized medicine using 
biomarkers that characterize disease severity and/or therapeutic 
response and particularly pharmacogenomics to target genetically 
identifi able response populations. We predict that the new models 
we develop in the laboratory, in the CRC and in the community 
will be used to improve existing and future therapies by generating 
the data that enable targeting them to susceptible populations 
and even individual patients who are likely to achieve the most 
benefi t with the least adversity from specifi c treatments. One 
nationally recognized example of such a genetic information 
based recommendation to not use a treatment was the fi nding 
by Dr. David Flockhart at IUSM that some patients with breast 
cancer who have a certain gene do not benefi t from a commonly 
used drug tamoxifen. 
 Th is program was made possible by institutional commitment 
from IU School of Medicine and Eli Lilly. Specifi cally, Eli Lilly 
agreed to support three new training positions per year and the 
recruitment of one new faculty member to direct the program 
who is supported fully for the fi rst three years. Th e fi nancial 
commitment by Lilly is approximately $1 million per year matched 
by in kind and other support from the CTSI. Work space for faculty 
and fellows is provided primarily at the IU School of Medicine 
in the Division of Clinical Pharmacology and fl exible space is 
available at Lilly as well so that fellows will be able to regularly 
interact with faculty from both institutions. Eli Lilly and IU School 
of Medicine will collaborate to provide appropriate infrastructure 
that supports modeling and simulation analysis computing time. 
In addition, there is support for some pilot modeling projects by 
the fellows in collaboration with supervising faculty. 
 Partnership with philanthropy: physician scientists program 
with Lilly endowment 
 Another major partnership that has boosted the mission of the 
Indiana CTSI is a grant of $60 million that the Lilly Endowment 
provided at the end of 2009 to the IU School of Medicine (IUSM) 
to create a Physician Scientist Program. Th e major portion of these 
funds is to help recruit at least 20 physician scientists to IUSM. 
Another $10 Million will be utilized as an endowment for the 
NIH-funded Medical Scientist Training Program (MSTP). Th is 
extraordinary support from the Lilly Endowment was guided by 
their keen awareness of the national crisis of the ever decreasing 
number of clinician-scientists and the need to train, attract 
and retain physician scientists in Indiana. Th is was a mutually 
important mission to both IUSM and the Endowment. Th ese 
discussions with the Endowment occurred under the leadership 
of Dr. D. Craig Brater, Dean, and Dr. David Wilkes, the Executive 
Associate Dean for Research at IUSM, who were able to convey 
this message of mutually important goals and convinced the 
philanthropic organization that it can be accomplished with a 
partnership. In addition, about 8 million will support a robust 
biorepository under the auspices of the Indiana CTSI. Th is 
ongoing longitudinal collection of biological specimen connected 
to phenotypic annotations and electronic medical record will be 
lasting resource for future physician scientists. 
 While these are some of the unique partnerships with Indiana 
CTSI, there are a number of other partnerships that are not 
listed here. For example, Richard M. Fairbanks Foundation 
is another philanthropic organization based in Indianapolis 
that has partnered with ICTSI toward enhancing health care 
and research. It has awarded grants of over $2.4 million to 
enhance the CTSI’s community activities and administrative 
operations. In summary, partnering with private corporations 
and philanthropic organizations is an important step in creating 
a successful CTSI. Th ese partners bring not only enormous local 
resources to facilitate translational research, but also provide 
help setting clear goals and deliverables that are guided by their 
business practices. Th is level of discipline and metrics based 
resource allocation makes the CTSI much more eff ective in 
accomplishing its mission. 
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